N4 Pharma PLC AAV Viral Vector Update (8399Y)
08 January 2024 - 6:00PM
UK Regulatory
TIDMN4P
RNS Number : 8399Y
N4 Pharma PLC
08 January 2024
8(th) January 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
AAV Viral Vector Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments,
gene therapy and vaccines, is pleased to provide a further
successful update on its ongoing research work into the use of
Nuvec (R) to enhance the performance of viral vectors.
Through its research programme with the University of Brunel,
the Company has demonstrated via a series of in vitro experiments
that Nuvec(R) can deliver increased transduction efficacy, when
complexed with Adeno-Associated virus 8 ("AAV8"). This follows on
from earlier work where the Company showed that Nuvec(R) increased
transduction efficacy of a standard Adenovirus vector.
Specifically, Nuvec(R) was mixed with AAV8 carrying a
fluorescent green protein gene and used to transduce human-like
liver cells (induced pluripotent cell model). When the viral vector
was complexed with Nuvec (R) , transduction efficacy increased
2.5-fold compared to the AAV8 vector when used on a standalone
basis . AAV8 was chosen for investigation as this virus is
currently being used for products already in clinical
development.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"The number of approvals of new gene therapies and the need for
appropriate delivery systems have reached unprecedented highs and
demand is growing exponentially. The AAV vector market alone (AAV
based gene therapy and AAV manufacturing) is projected to grow from
USD 1.9 billion in 2022 to USD 11.1 billion by 2035, a CAGR of
14%(1).
"For in vivo gene therapy, the Adenovirus (AV) and
Adeno-Associated virus (AAV) are acknowledged as the most used
delivery vehicles . However relatively high amounts of AV and AAV
are needed to be clinically efficient and this appears directly
correlated with adverse events in patients such as unwanted
immunogenicity and potential safety implications.
"Our work shows that Nuvec(R) has the potential to reduce the
amount of AV and AAV needed and thus decrease both the cost of
goods and immunogenicity associated with using these viral vectors.
We believe this will be a major focus of the pharma/biotech
industry as these viral vector delivery systems are further
investigated .
"This work is running in parallel to our ongoing oral and dual
loading work as well as the Nanogenics' Glaucoma product, an update
on which will follow soon. "
(1)Adeno-Associated Viral Vectors / AAV Vector Market - Focus on
AAV Based Gene Therapy and AAV Manufacturing by Type of Therapy,
Type of Gene Delivery Method Used, Target Therapeutic Area,
Application Area, Scale of Operation and Geographical Regions:
Industry Trends and Global Forecasts, 2022-2035: Roots
analysis.
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO Via N4 Pharma Investor
Luke Cairns, Executive Director Hub
Engage with us directly at N4 Pharma
Investor Hub Sign up at investors.n4pharma.com
To hear more, visit https://investors.n4pharma.com/link/2P2xwe
SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Kasia Brzozowska (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
---------------------------------------------
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657 0050
Joint Broker
Andy Thacker
James Pope
---------------------------------------------
IFC Advisory Ltd Tel: +44(0)20 3934 6630
Financial PR
Graham Herring
Zach Cohen
---------------------------------------------
Glossary
AAV8 is an isolate from rhesus monkey tissue with high homology
to other AAVs , but it has a liver cell transduction efficiency
reported to be far greater than those of all others AAVs tested to
date.
pluripotent cell model: T he term "pluripotent" means capable of
developing into differentiated cells. Pluripotent cells are the
embryonic stem cells that have the unlimited capacity to divide,
self-renew and differentiate into cells of early primary germ cell
layers, namely mesoderm, endoderm, and ectoderm
transduction: the transfer of genetic material from one organism
to another by a genetic vector
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for oncology, gene therapy and vaccines using
its unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens in these fields to use Nuvec(R) as the
delivery vehicle for these antigens. As these products progress
through pre--clinical and clinical programs, N4 Pharma will seek to
receive upfront payments, milestone payments and ultimately royalty
payments once products reach the market.
For further information on the Company visit www.n4pharma.com or
sign up at investors.n4pharma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBUGDBDGGDGSU
(END) Dow Jones Newswires
January 08, 2024 02:00 ET (07:00 GMT)
N4 Pharma (AQSE:N4P.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
N4 Pharma (AQSE:N4P.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
